Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F24%3A00584812" target="_blank" >RIV/86652036:_____/24:00584812 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/24:43926666 RIV/00216208:11140/24:10475509 RIV/00064173:_____/24:43926666

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S2589004224002657?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S2589004224002657?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.isci.2024.109044" target="_blank" >10.1016/j.isci.2024.109044</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Popis výsledku v původním jazyce

Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 G 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumorbearing mice at small doses (%3 mg/kg). SB-T-121605 and SB-T121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing.

Název v anglickém jazyce

Third-generation taxanes SB-T-121605 and SB-T-121606 are effective in pancreatic ductal adenocarcinoma

Popis výsledku anglicky

Pancreatic cancer is a severe malignancy with increasing incidence and high mortality due to late diagnosis and low sensitivity to treatments. Search for the most appropriate drugs and therapeutic regimens is the most promising way to improve the treatment outcomes of the patients. This study aimed to compare (1) in vitro efficacy and (2) in vivo antitumor effects of conventional paclitaxel and the newly synthesized second (SB-T-1216) and third (SB-T-121605 and SB-T-121606) generation taxanes in KRAS wild type BxPC-3 and more aggressive KRAS G12V mutated Paca-44 pancreatic cancer cell line models. In vitro, paclitaxel efficacy was 27.6 G 1.7 nM, while SB-Ts showed 1.7-7.4 times higher efficacy. Incorporation of SB-T121605 and SB-T-121606 into in vivo therapeutic regimens containing paclitaxel was effective in suppressing tumor growth in Paca-44 tumorbearing mice at small doses (%3 mg/kg). SB-T-121605 and SB-T121606 in combination with paclitaxel are promising candidates for the next phase of preclinical testing.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

iScience

ISSN

2589-0042

e-ISSN

2589-0042

Svazek periodika

27

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

15

Strana od-do

109044

Kód UT WoS článku

001182148700001

EID výsledku v databázi Scopus

2-s2.0-85184767975